Bin Yu is a research laboratory coordinator in Clinic Science Division at H Lee Moffitt Cancer Research Center. She graduated from Nursing School of Chongqing Medical University in 1988 and had been worked in Intensive Care and Emergency Department, First affiliated Hospital of Chongqing Medical University (FAH-CMU) for five years. After 5 years clinical practice, she started her research path in Cardiovascular Department of FAH-CMU on a project on epidemic investigation of rheumatism in children caused by group A hemolytic streptococci infection in south-west of China for 6 years.
After moving to the United States, she joined H Lee Moffitt Cancer Research Center in 2000. For the first 2 years, she worked as a research assistant with Dmitry Gabrilovich on pre-clinical studies including combination of dendritic cell vaccine and chemotherapy, and ATRA induced myeloid-derived suppressor cell (MDSC) differentiation to improve anti-tumor immune response. In the next 4 years, she worked in Eric Haura's lab as a research associate on establishing a CreERT2/Flox-STAT3 mouse line to investigate STAT3 role of promoting lung wound and cancer occurrence. From 2007 t0 2015, she worked with Jeffrey Weber on monitoring clinic trials of T cell check point inhibition of anti-PD-1 and anti-CTLA4 in Cutaneous Research Center, and pre-clinical study of improving anti-PD-1 and anti-CTLA4 efficacy by depletion of MDSCs.
Since joined Marco Davila's lab in 2015, she has been working on improving CAR T cell transduction efficiency, CAR T expansion by AAPC (artificial antigen presenting cells) and AAPC effect on gamma delta T cells or gamma delta CAR T cells that are not MHC class I restricted but having cytolytic function towards target cells.
